Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

被引:430
作者
Kupperman, Erik [1 ]
Lee, Edmund C. [1 ]
Cao, Yueying [1 ]
Bannerman, Bret [1 ]
Fitzgerald, Michael [1 ]
Berger, Allison [1 ]
Yu, Jie [1 ]
Yang, Yu [1 ]
Hales, Paul [1 ]
Bruzzese, Frank [1 ]
Liu, Jane [1 ]
Blank, Jonathan [1 ]
Garcia, Khristofer [1 ]
Tsu, Christopher [1 ]
Dick, Larry [1 ]
Fleming, Paul [1 ]
Yu, Li [1 ]
Manfredi, Mark [1 ]
Rolfe, Mark [1 ]
Bolen, Joe [1 ]
机构
[1] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
MANTLE CELL LYMPHOMA; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; RELAPSED MULTIPLE-MYELOMA; NON-HODGKINS-LYMPHOMA; EXTENDED FOLLOW-UP; PHASE-II; 20S PROTEASOME; IRREVERSIBLE INHIBITOR; ANTICANCER DRUGS;
D O I
10.1158/0008-5472.CAN-09-2766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, several groups are pursuing the development of additional small-molecule proteasome inhibitors for both hematologic and solid tumor indications. Here, we describe MLN9708, a selective, orally bioavailable, secondgeneration proteasome inhibitor that is in phase I clinical development. MLN9708 has a shorter proteasome dissociation half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib. MLN9708 has a larger blood volume distribution at steady state, and analysis of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib. MLN9708 showed activity in both solid tumor and hematologic preclinical xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity. Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage. Taken together, these data support the clinical development of MLN9708 for both hematologic and solid tumor indications. Cancer Res; 70(5); 1970-80. (C)2010 AACR.
引用
收藏
页码:1970 / 1980
页数:11
相关论文
共 53 条
[11]   NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model [J].
Cusack, James C., Jr. ;
Liu, Rong ;
Xia, Lijun ;
Chao, Ta-Hsiang ;
Pien, Christine ;
Niu, Wei ;
Palombella, Vito J. ;
Neuteboom, Saskia T. C. ;
Palladino, Michael A. .
CLINICAL CANCER RESEARCH, 2006, 12 (22) :6758-6764
[12]   The proteasome [J].
Dalton, WS .
SEMINARS IN ONCOLOGY, 2004, 31 (06) :3-9
[13]   The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis [J].
Delic, J ;
Masdehors, P ;
Ömura, S ;
Cosset, JM ;
Dumont, J ;
Binet, JL ;
Magdelénat, H .
BRITISH JOURNAL OF CANCER, 1998, 77 (07) :1103-1107
[14]   Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome [J].
Demo, Susan D. ;
Kirk, Christopher J. ;
Aujay, Monette A. ;
Buchholz, Tonia J. ;
Dajee, Maya ;
Ho, Mark N. ;
Jiang, Jing ;
Laidig, Guy J. ;
Lewis, Evan R. ;
Parlati, Francesco ;
Shenk, Kevin D. ;
Smyth, Mark S. ;
Sun, Congcong M. ;
Vallone, Marcy K. ;
Woo, Tina M. ;
Molineaux, Christopher J. ;
Bennett, Mark K. .
CANCER RESEARCH, 2007, 67 (13) :6383-6391
[15]   Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer [J].
Dorsey, Bruce D. ;
Iqbal, Mohamed ;
Chatterjee, Sankar ;
Menta, Ernesto ;
Bernardini, Raffaella ;
Bernareggi, Alberto ;
Cassara, Paolo G. ;
D'Arasmo, Germano ;
Ferretti, Edmondo ;
De Munari, Sergio ;
Oliva, Ambrogio ;
Pezzoni, Gabriella ;
Allievi, Cecilia ;
Strepponi, Ivan ;
Ruggeri, Bruce ;
Ator, Mark A. ;
Williams, Michael ;
MallamoT, John P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) :1068-1072
[16]  
Elliott Peter J, 2003, Methods Mol Med, V85, P163
[17]   Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].
Fisher, Richard I. ;
Bernstein, Steven H. ;
Kahl, Brad S. ;
Djulbegovic, Benjamin ;
Robertson, Michael J. ;
de Vos, Sven ;
Epner, Elliot ;
Krishnan, Amrita ;
Leonard, John P. ;
Lonial, Sagar ;
Stadtmauer, Edward A. ;
O'Connor, Owen A. ;
Shi, Hongliang ;
Boral, Anthony L. ;
Goy, Andre .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874
[18]   Proteasome inhibitor PS-341 induces a apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells [J].
Fribley, A ;
Zeng, QH ;
Wang, CY .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (22) :9695-9704
[19]   Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma [J].
Goy, A ;
Younes, A ;
McLaughlin, P ;
Pro, B ;
Romaguera, JE ;
Hagemeister, F ;
Fayad, L ;
Dang, NH ;
Samaniego, F ;
Wang, M ;
Broglio, K ;
Samuels, B ;
Gilles, F ;
Sarris, AH ;
Hart, S ;
Trehu, E ;
Schenkein, D ;
Cabanillas, F ;
Rodriguez, AM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :667-675
[20]  
Hai T, 1999, GENE EXPRESSION, V7, P321